🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Ono Pharmaceutical Co Ltd (OPHLY)

OTC Markets
Currency in USD
3.96
-0.08(-1.98%)
Closed
OPHLY Scorecard
Full Analysis
Management has been aggressively buying back shares
Unusual trading volume
Fair Value
Day's Range
3.923.98
52 wk Range
3.926.43
Key Statistics
Edit
Prev. Close
3.96
Open
3.98
Day's Range
3.92-3.98
52 wk Range
3.92-6.43
Volume
754,450
Average Volume (3m)
243,849
1-Year Change
-31.84%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
OPHLY Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 4 consecutive years
Show more

Ono Pharmaceutical Co Ltd Company Profile

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer’s disease; Ongentys tablets for Parkinson’s disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.

Employees
3761

Compare OPHLY to Peers and Sector

Metrics to compare
OPHLY
Peers
Sector
Relationship
P/E Ratio
9.1x22.5x−0.7x
PEG Ratio
−0.430.140.00
Price/Book
1.1x2.0x2.6x
Price / LTM Sales
1.8x2.3x3.2x
Upside (Analyst Target)
-19.8%45.2%
Fair Value Upside
Unlock11.9%7.0%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 201.57
Dividend Yield
-
Annualized payout
-
5-Years Growth
-
Growth Streak

People Also Watch

100.48
ACLX
-5.68%
3.71
ZNTL
-7.94%
30.07
OTSKY
-2.37%
3.640
ABSI
-14.95%
8.86
FHTX
-4.53%

FAQ

What Is the Ono Pharmaceutical Co (OPHLY) Stock Price Today?

The Ono Pharmaceutical Co stock price today is 3.96

What Stock Exchange Does Ono Pharmaceutical Co Trade On?

Ono Pharmaceutical Co is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Ono Pharmaceutical Co?

The stock symbol for Ono Pharmaceutical Co is "OPHLY."

What Is the Ono Pharmaceutical Co Market Cap?

As of today, Ono Pharmaceutical Co market cap is 5.61B.

What is Ono Pharmaceutical Co Earnings Per Share?

The Ono Pharmaceutical Co EPS is 201.57.

What Is the Next Ono Pharmaceutical Co Earnings Date?

Ono Pharmaceutical Co will release its next earnings report on Jan 31, 2025.

From a Technical Analysis Perspective, Is OPHLY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.